Statistik Asas
| LEI | 549300H76KXCAAGUS878 |
| CIK | 924717 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Surmodics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name |
|
| August 8, 2025 |
EXHIBIT 99.1 Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance August 8, 2025 07:00 a.m. ET EDEN PRAIRIE, Minn. – Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2025, and updated |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2025 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 2, 2025 |
FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2025 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Surmodics, Inc. (Exact name of registrant as specified in its charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 9924 West 74th Street Eden Prairie, Minnesota 55344 (Address of Principal Executive Offices) (Zip Code) |
|
| May 20, 2025 |
Exhibit 1.01 – Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form EXHIBIT 1.01 Conflict Minerals Report of Surmodics, Inc. This Conflict Minerals Report of Surmodics, Inc. (the “Company”, “we” or “our”) for the period from January 1, 2024 to December 31, 2024, has been prepared pursuant to Rule 13p-1 and Form SD (together, the “Rule”) promulgated under Section 13(p) of the Securities Exchange Act of 1934, as amended. The Rule requires disclosure of certain infor |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 30, 2025 |
EXHIBIT 99.1 Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance April 30, 2025 07:00 a.m. ET EDEN PRAIRIE, Minn. – Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and i |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact nam |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 7, 2025 |
Exhibit 99.1 Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR March 6, 2025 at 9:00 PM EST EDEN PRAIRIE, Minn.— March 6, 2025 — Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today provided the following statement in response to the |
|
| February 13, 2025 |
AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection wi |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 06, 2025 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 30, 2025 |
Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results EXHIBIT 99.1 Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results January 30, 2025 07:00 a.m. ET EDEN PRAIRIE, Minn. – Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2024. First Quarter Fiscal 2025 Financial Summary • Tota |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact |
|
| January 30, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2025 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 22, 2025 |
EXHIBIT 1 EXHIBIT A JOINT FILING AGREEMENT Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, Soleus Capital Management, L.P., a Delaware limited partnership, Soleus GP, LLC, a Delaware limited liability company, and Guy Levy, an individual, here |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| November 20, 2024 |
Surmodics, Inc. Securities Trading Policy. EXHIBIT 19.1 SURMODICS, INC. SECURITIES TRADING POLICY I. Purpose and Policy Statement Federal and state securities laws make it illegal for anyone to trade in a company’s securities while in possession of material, nonpublic information relating to that company. Therefore, it is a violation of the policies of Surmodics, Inc. (“Surmodics” or the “Company”) for any officer, director, or employee of |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-23837 Surmodics, Inc. |
|
| November 20, 2024 |
Subsidiaries of the Registrant. EXHIBIT 21 SURMODICS, INC. SUBSIDIARIES Name State of Incorporation Surmodics IVD, Inc. Maryland NorMedix, Inc. Minnesota Creagh Medical Limited Ireland SurModics MD, LLC Minnesota Surmodics MD Operations, LLC Minnesota Surmodics Coatings, LLC Minnesota Surmodics Coatings Mfg, LLC Minnesota Surmodics Holdings, LLC Minnesota Surmodics Shared Services, LLC Minnesota Vetex Medical Limited Ireland |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* SURMODICS, INC. (Name of Issuer) Common Stock, $0.05 par value per share (Title of Class of Securities) 868873100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| November 6, 2024 |
Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results EXHIBIT 99.1 Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results November 6, 2024 07:00 a.m. ET EDEN PRAIRIE, Minn. – Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. Fourth Quarter Fiscal 2024 Fin |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2024 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| October 23, 2024 |
EXHIBIT 1: Agreement to Make a Joint Filing EX-1 2 tm2426490d2ex-1.htm EXHIBIT 1 CUSIP No. 868873100 Schedule 13G Page 1 of 1 Exhibit 1 EXHIBIT 1 TO SCHEDULE 13G October 23, 2024 In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, TRIGRAN INVESTMENTS, INC., DOUGLAS GRANAT, LAWRENCE A. OBERMAN, STEVEN G. SIMON, BRADLEY F. SIMON and STEVEN R. MONIESON each hereby agree to the joint filing of this stateme |
|
| October 23, 2024 |
SRDX / Surmodics, Inc. / Trigran Investments, Inc. - SC 13G/A Passive Investment SC 13G/A 1 tm2426490d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 Under the Securities Exchange Act of 1934 (Amendment No. 13)* SURMODICS, INC. (Name of Issuer) Common Stock, Par Value of $0.05 Per Share (Title of Class of Securities) 868873100 (CUSIP Number) September 30, 2024 |
|
| October 23, 2024 |
SRDX / Surmodics, Inc. / TRIGRAN INVESTMENTS LP - SC 13G/A Passive Investment SC 13G/A 1 tm2426493d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 Under the Securities Exchange Act of 1934 (Amendment No. 2)* SURMODICS, INC. (Name of Issuer) Common Stock, Par Value of $0.05 Per Share (Title of Class of Securities) 868873100 (CUSIP Number) September 30, 2024 |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2024 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name of registrant as |
|
| July 31, 2024 |
Exhibit 3.2 RESTATED BYLAWS OF SURMODICS, INC. As amended August 27, 2024 ARTICLE 1. OFFICES 1.1) Offices. The corporation may have offices at such places within or without the State of Minnesota as the Board of Directors shall from time to time determine or the business of the corporation requires. ARTICLE 2. MEETINGS OF SHAREHOLDERS 2.1) Annual Meeting. The annual meeting of the shareholders of |
|
| July 31, 2024 |
Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results EXHIBIT 99.1 Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results July 31, 2024 07:00 a.m. ET EDEN PRAIRIE, Minn. – Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2024. Third Quarter Fiscal 2024 Financial Summary • Total Reven |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| July 9, 2024 |
SRDX / Surmodics, Inc. / Trigran Investments, Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 Under the Securities Exchange Act of 1934 (Amendment No. 12)* SURMODICS, INC. (Name of Issuer) Common Stock, Par Value of $0.05 Per Share (Title of Class of Securities) 868873100 (CUSIP Number) June 12, 2024 Date of Event Which Requires Filing of the Sta |
|
| July 9, 2024 |
EXHIBIT 1: Agreement to Make a Joint Filing EX-1 2 tm2419034d1ex1.htm EXHIBIT 1 Exhibit 1 CUSIP No. 868873100 Schedule 13G Page 1 of 1 EXHIBIT 1 TO SCHEDULE 13G July 9, 2024 In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, TRIGRAN INVESTMENTS, INC., DOUGLAS GRANAT, LAWRENCE A. OBERMAN, STEVEN G. SIMON, BRADLEY F. SIMON and STEVEN R. MONIESON each hereby agree to the joint filing of this statement on |
|
| July 8, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| June 27, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| June 27, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Surmodics, Inc. |
|
| June 10, 2024 |
SRDX / Surmodics, Inc. / Beryl Capital Management LLC Passive Investment SC 13G 1 srdx13g.htm Sur UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Surmodics, Inc. (Name of Issuer) Common Stock, par value $0.05 per share (Title of Class of Securities) 868873100 (CUSIP Number) May 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 28, 2024 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 29, 2024 |
EX-10.1 Exhibit 10.1 SURMODICS, INC. EXECUTIVE TRANSACTION BONUS PROGRAM This Executive Transaction Bonus Program (this “Program”) is established by Surmodics, Inc. (the “Company”), effective as of May 27, 2024 (the “Effective Date”). 1. PURPOSES OF THE PROGRAM. The board of directors of the Company (the “Board”) desires to provide its executive officer of the Company, subject to Section 16 of the |
|
| May 29, 2024 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION MERGER AGREEMENT among BCE PARENT, LLC (“Parent”) BCE MERGER SUB, INC. (“Merger Sub”) and SURMODICS, INC. (the “Company”) Dated as of May 28, 2024 TABLE OF CONTENTS Page Article 1 THE MERGER AND THE CLOSING 2 Section 1.1 The Merger 2 Section 1.2 Merger Closing 2 Section 1.3 Further Action 2 Article 2 EFFECT OF THE MERGER 3 Section 2.1 Effect of Merger; Organiza |
|
| May 29, 2024 |
EX-99.1 Exhibit 99.1 For Release 7:00 a.m. (EDT) May 29, 2024 Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million Eden Prairie, Minn. — May 29, 2024 — Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that i |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 28, 2024 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 29, 2024 |
Amendment to the Restated Bylaws of Surmodics, Inc. EX-3.1 Exhibit 3.1 Surmodics, Inc. (the “Company”) Bylaw Amendment The Restated Bylaws of the Company are hereby amended by inserting the following new Article 10 at the end thereof: ARTICLE 10. EXCLUSIVE FORUM 10.1) Exclusive Forum. Unless the corporation consents in writing to the selection of an alternative forum (which consent may be given at any time, including during the pendency of litigati |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 24, 2024 |
Exhibit 1.01 – Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form EXHIBIT 1.01 Conflict Minerals Report of Surmodics, Inc. This Conflict Minerals Report of Surmodics, Inc. (the “Company”, “we” or “our”) for the period from January 1, 2023 to December 31, 2023, has been prepared pursuant to Rule 13p-1 and Form SD (together, the “Rule”) promulgated under Section 13(p) of the Securities Exchange Act of 1934, as amended. The Rule requires disclosure of certain infor |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Surmodics, Inc. (Exact name of registrant as specified in its charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 9924 West 74th Street Eden Prairie, Minnesota 55344 (Address of Principal Executive Offices) (Zip Code) |
|
| May 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 01, 2024 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name of registrant as |
|
| May 1, 2024 |
EXHIBIT 99.1 Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance Announces Commercial Launch of Two New Thrombectomy Devices for the Venous and Arterial Vasculatures: Pounce™ Venous and Pounce LP (Low Profile) May 1, 2024 07:00 a.m. ET EDEN PRAIRIE, Minn. – Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vi |
|
| February 13, 2024 |
SRDX / Surmodics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02022-surmodicsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Surmodics Inc Title of Class of Securities: Common Stock CUSIP Number: 868873100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rul |
|
| February 12, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 08, 2024 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 9, 2024 |
SRDX / Surmodics, Inc. / Trigran Investments, Inc. - SC 13G/A Passive Investment SC 13G/A 1 tm243940d8sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 Under the Securities Exchange Act of 1934 (Amendment No. 11)* SURMODICS, INC. (Name of Issuer) Common Stock, Par Value of $0.05 Per Share (Title of Class of Securities) 868873100 (CUSIP Number) December 31, 2023 D |
|
| February 9, 2024 |
EXHIBIT 1: Agreement to Make a Joint Filing EX-1 2 tm243940d8ex1.htm EXHIBIT 1 CUSIP No. 868873100 Schedule 13G Page 1 of 1 Exhibit 1 EXHIBIT 1 TO SCHEDULE 13G February 9, 2024 In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, TRIGRAN INVESTMENTS, INC., DOUGLAS GRANAT, LAWRENCE A. OBERMAN, STEVEN G. SIMON, BRADLEY F. SIMON and STEVEN R. MONIESON each hereby agree to the joint filing of this statement |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Surmodics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 868873100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name of registrant |
|
| February 1, 2024 |
EXHIBIT 99.1 Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance February 1, 2024 07:00 a.m. ET EDEN PRAIRIE, Minn. – Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2023, and u |
|
| February 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 01, 2024 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 29, 2024 |
SRDX / Surmodics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) SURMODICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.05 PER SHARE (Title of Class of Securities) 868873100 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule purs |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| November 22, 2023 |
Surmodics, Inc. Policy on Recovery of Erroneously Awarded Compensation EXHIBIT 97.1 Surmodics, Inc. Policy on Recovery of Erroneously Awarded Compensation Effective June 22, 2023 Policy The Board of Directors (the “Board”) of Surmodics, Inc. has adopted this Policy on Recovery of Erroneously Awarded Compensation (this “Policy”) pursuant to Rule 10D-1 of the Securities and Exchange Act of 1934 (“Rule 10D-1”), the Securities and Exchange Commission (the “SEC”) regulati |
|
| November 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-23837 Surmodics, Inc. |
|
| November 22, 2023 |
Subsidiaries of the Registrant. EXHIBIT 21 SURMODICS, INC. SUBSIDIARIES Name State of Incorporation Surmodics IVD, Inc. Maryland NorMedix, Inc. Minnesota Creagh Medical Limited Ireland SurModics MD, LLC Minnesota Surmodics MD Operations, LLC Minnesota Surmodics Coatings, LLC Minnesota Surmodics Coatings Mfg, LLC Minnesota Surmodics Holdings, LLC Minnesota Surmodics Shared Services, LLC Minnesota Vetex Medical Limited Ireland |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2023 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 8, 2023 |
EXHIBIT 99.1 Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance November 8, 2023 07:00 a.m. ET EDEN PRAIRIE, Minn. – Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended Se |
|
| August 2, 2023 |
EXHIBIT 99.1 Surmodics Reports Third Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance August 2, 2023 07:00 a.m. ET EDEN PRAIRIE, Minn. – Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2023, and updated |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 02, 2023 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name of registrant as |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| July 26, 2023 |
EXHIBIT 3.2 RESTATED BYLAWS OF SURMODICS, INC. As amended July 20, 2023 ARTICLE 1. OFFICES 1.1) Offices. The corporation may have offices at such places within or without the State of Minnesota as the Board of Directors shall from time to time determine or the business of the corporation requires. ARTICLE 2. MEETINGS OF SHAREHOLDERS 2.1) Annual Meeting. The annual meeting of the shareholders of th |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 20, 2023 |
Exhibit 99.1 Surmodics Receives FDA Approval for the SurVeil™ Drug-Coated Balloon Surmodics to receive $27 million milestone payment from Abbott June 20, 2023 06:30 a.m. Eastern Daylight Time EDEN PRAIRIE, Minn.—(BUSINESS WIRE)—Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the receipt of U.S. Fo |
|
| June 8, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 08, 2023 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 8, 2023 |
Gary Maharaj President and CEO Tim Arens Senior Vice President of Finance, IT and CFO June 2023 © 2023 Surmodics, Inc. |
|
| May 25, 2023 |
Exhibit 1.01 – Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form EXHIBIT 1.01 Conflict Minerals Report of Surmodics, Inc. This Conflict Minerals Report of Surmodics, Inc. (the “Company”, “we” or “our”) for the period from January 1, 2022 to December 31, 2022, has been prepared pursuant to Rule 13p-1 and Form SD (together, the “Rule”) promulgated under Section 13(p) of the Securities Exchange Act of 1934, as amended. The Rule requires disclosure of certain infor |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Surmodics, Inc. (Exact name of registrant as specified in its charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 9924 West 74th Street Eden Prairie, Minnesota 55344 (Address of Principal Executive Offices) (Zip Code) |
|
| May 19, 2023 |
United States securities and exchange commission logo May 19, 2023 Gary Maharaj Chief Executive Officer Surmodics, Inc. |
|
| May 19, 2023 |
Surmodics, Inc. 9924 West 74th Street Eden Prairie, Minnesota 55344 Surmodics, Inc. 9924 West 74th Street Eden Prairie, Minnesota 55344 May 19, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Surmodics, Inc. Registration Statement on Form S-3 File No. 333-271874 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Surmodics, Inc. hereby respectfully |
|
| May 12, 2023 |
As filed with the Securities and Exchange Commission on May 12, 2023 S-8 1 srdxforms-82023-05.htm S-8 As filed with the Securities and Exchange Commission on May 12, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S‑8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Surmodics, Inc. (Exact name of Registrant as specified in its charter) Minnesota (State or other jurisdiction of incorporation or organizatio |
|
| May 12, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charters) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry F |
|
| May 12, 2023 |
As filed with the Securities and Exchange Commission on May 12, 2023 As filed with the Securities and Exchange Commission on May 12, 2023 Registration No. |
|
| May 12, 2023 |
EXHIBIT 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.05 par valu |
|
| April 26, 2023 |
EXHIBIT 10.1 (Execution Copy) FIFTH ADDENDUM TO LEASE THIS FIFTH ADDENDUM TO LEASE (“Fifth Addendum”) is entered into as of the 24th day of February, 2023 (“Effective Date”), by and between MN Golden 1, LLC and MN Golden 2, LLC (as tenants in common), both being Minnesota limited liability companies (collectively, “Landlord”), and Surmodics, Inc., a Minnesota corporation (“Tenant”). WITNESSETH: WH |
|
| April 26, 2023 |
EXHIBIT 99.1 Surmodics Reports Second Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance April 26, 2023 07:00 a.m. ET EDEN PRAIRIE, Minn. – Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2023, and upda |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 28, 2023 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Id |
|
| March 28, 2023 |
Exhibit 99.1 Surmodics Provides Regulatory Update on its Strategy to Submit an Amended Premarket Approval Application for the SurVeil™ Drug-Coated Balloon Announces Receipt of Positive Formal FDA Feedback via the Q-Submission Program Substantially reduces the anticipated time and cost needed to receive a PMA EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-March 28, 2023-Surmodics, Inc. (NASDAQ:SRDX), a leadin |
|
| March 20, 2023 |
SRDX / Surmodics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 SRDXSC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SURMODICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.05 PER SHARE (Title of Class of Securities) 868873100 (CUSIP Number) MARCH 15, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pu |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 15, 2023 |
Gary Maharaj President and CEO Tim Arens Senior Vice President of Finance, IT and CFO March 2023 © 2023 Surmodics, Inc. |
|
| February 14, 2023 |
SRDX / SurModics, Inc. / Soleus Capital Master Fund, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d459434dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Surmodics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 868873100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 13, 2023 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 9, 2023 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer |
|
| February 10, 2023 |
EX-99.1 2 tm235856d10ex99-1.htm EXHIBIT 1 CUSIP No. 868873100 Schedule 13G Page 1 of 1 Exhibit 1 EXHIBIT 1 TO SCHEDULE 13G February 10, 2023 In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, TRIGRAN INVESTMENTS, INC., DOUGLAS GRANAT, LAWRENCE A. OBERMAN, STEVEN G. SIMON, BRADLEY F. SIMON and STEVEN R. MONIESON each hereby agree to the joint filing of this s |
|
| February 10, 2023 |
SRDX / SurModics, Inc. / TRIGRAN INVESTMENTS LP - SC 13G/A Passive Investment SC 13G/A 1 tm235857d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 Under the Securities Exchange Act of 1934 (Amendment No. 1)* SURMODICS, INC. (Name of Issuer) Common Stock, Par Value of $0.05 Per Share (Title of Class of Securities) 868873100 (CUSIP Number) December 31, 2022 Da |
|
| February 10, 2023 |
SRDX / SurModics, Inc. / Trigran Investments, Inc. - SC 13G/A Passive Investment SC 13G/A 1 tm235856d10sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 Under the Securities Exchange Act of 1934 (Amendment No. 10)* SURMODICS, INC. (Name of Issuer) Common Stock, Par Value of $0.05 Per Share (Title of Class of Securities) 868873100 (CUSIP Number) December 31, 2022 |
|
| February 9, 2023 |
SRDX / SurModics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01993-surmodicsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Surmodics Inc. Title of Class of Securities: Common Stock CUSIP Number: 868873100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the ru |
|
| February 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 06, 2023 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name of registrant |
|
| February 6, 2023 |
EXHIBIT 99.1 Surmodics Reports First Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance February 6, 2023 04:00 p.m. Eastern Standard Time EDEN PRAIRIE, Minn. – Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended Decem |
|
| February 3, 2023 |
Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 30, 2023 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer |
|
| January 19, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 19, 2023 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer |
|
| January 19, 2023 |
Exhibit 99.1 Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil™ Drug-Coated Balloon EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-January 19, 2023-Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has received a letter from the U.S. Food and Drug Adminis |
|
| December 19, 2022 |
DEF 14A 1 srdx-def14a20230209.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Onl |
|
| December 19, 2022 |
srdx-defa14a20230209.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ??? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, For Use of the Commission Only (as permitted b |
|
| November 23, 2022 |
Subsidiaries of the Registrant. Exhibit 21 SURMODICS, INC. SUBSIDIARIES Name State of Incorporation Surmodics IVD, Inc. Maryland NorMedix, Inc. Minnesota Creagh Medical Limited Ireland SurModics MD, LLC Minnesota Surmodics MD Operations, LLC Minnesota Surmodics Coatings, LLC Minnesota Surmodics Coatings Mfg, LLC Minnesota Surmodics Holdings, LLC Minnesota Surmodics Shared Services, LLC Minnesota Vetex Medical Limited Ireland |
|
| November 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-23837 Surmodics, Inc. |
|
| November 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2022 Surmodics, Inc. (Exact name of Registrant as Specified in Its Charter) Minnesota 0-23837 41-1356149 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 9, 2022 |
EXHIBIT 99.1 Surmodics Reports Fourth Quarter and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Financial Guidance November 9, 2022 07:00 Eastern Standard Time EDEN PRAIRIE, Minn. – Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal |
|
| October 17, 2022 |
STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 14, 2022 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identif |
|
| October 17, 2022 |
Exhibit 10.1 Certain information contained in this document has been omitted either because it is not material or is the type that the registrant treats as private or confidential. Omitted portions are marked with [****] in this exhibit. The registrant agrees to furnish any omitted schedule (or similar attachments) to the Securities and Exchange Commission upon request. Execution Version CREDIT, S |
|
| September 2, 2022 |
SRDX / SurModics, Inc. / Soleus Capital Master Fund, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Surmodics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 868873100 (CUSIP Number) August 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| September 2, 2022 |
EXHIBIT A JOINT FILING AGREEMENT Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, and Mr. Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement is attached, and any amendments t |
|
| August 31, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 31, 2022 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer I |
|
| July 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name of registrant as |
|
| July 27, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 27, 2022 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Ide |
|
| July 27, 2022 |
Surmodics Reports Third Quarter Fiscal 2022 Results Exhibit 99.1 Surmodics Reports Third Quarter Fiscal 2022 Results EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-July 27, 2022-Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 third quarter ended June 30, 2022 and updated its financial outlook for its fiscal 2022. Summary of Third Q |
|
| May 27, 2022 |
Exhibit 1.01 – Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form EX-1.01 2 srdx-ex1016.htm EX-1.01 EXHIBIT 1.01 Conflict Minerals Report of Surmodics, Inc. This Conflict Minerals Report of Surmodics, Inc. (the “Company”, “we” or “our”) for the period from January 1, 2021 to December 31, 2021, has been prepared pursuant to Rule 13p-1 and Form SD (together, the “Rule”) promulgated under Section 13(p) of the Securities Exchange Act of 1934, as amended. The Rule re |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Surmodics, Inc. (Exact name of registrant as specified in its charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 9924 West 74th Street Eden Prairie, Minnesota 55344 (Address of Principal Executive Offices) (Zip Code) |
|
| May 17, 2022 |
SRDX / SurModics, Inc. / Trigran Investments, Inc. - SC 13G/A Passive Investment SC 13G/A 1 tm2215706d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 Under the Securities Exchange Act of 1934 (Amendment No. 9)* SURMODICS, INC. (Name of Issuer) Common Stock, Par Value of $0.05 Per Share (Title of Class of Securities) 868873100 (CUSIP Number) May 10, 2022 Date o |
|
| May 17, 2022 |
SRDX / SurModics, Inc. / TRIGRAN INVESTMENTS LP - SC 13G Passive Investment SC 13G 1 tm2215711d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 Under the Securities Exchange Act of 1934 (Amendment No.)* SURMODICS, INC. (Name of Issuer) Common Stock, Par Value of $0.05 Per Share (Title of Class of Securities) 868873100 (CUSIP Number) May 10, 2022 Date of Event |
|
| April 27, 2022 |
EXHIBIT 10.1 (Execution Copy) FOURTH ADDENDUM TO LEASE THIS FOURTH ADDENDUM TO LEASE (?Fourth Addendum?) is entered into as of the 16th day of March, 2022 (?Effective Date?), by and between MN Golden 1, LLC and MN Golden 2, LLC (as tenants in common), both being Minnesota limited liability companies having offices at 820 Morris Turnpike, Suite 301, Short Hills, New Jersey 07078 (collectively, ?Lan |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name of registrant as |
|
| April 27, 2022 |
Surmodics Reports Second Quarter Fiscal 2022 Results Exhibit 99.1 Surmodics Reports Second Quarter Fiscal 2022 Results EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-April 27, 2022-Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 second quarter ended March 31, 2022 and updated its financial outlook for its fiscal 2022. Summary of Sec |
|
| April 27, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 27, 2022 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Id |
|
| March 7, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 7, 2022 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Ide |
|
| March 7, 2022 |
Exhibit 10.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?) is made and entered into as of March 7, 2022, by and among SURMODICS, INC., a Minnesota corporation (?Borrower?), the other Loan Parties hereto, and BRIDGEWATER BANK, a Minnesota banking corporation (together with its successors and assigns, ?Lender?). RECITALS: A. B |
|
| February 23, 2022 |
EXHIBIT 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.05 par valu |
|
| February 23, 2022 |
As filed with the Securities and Exchange Commission on February 23, 2022 As filed with the Securities and Exchange Commission on February 23, 2022 Registration No. |
|
| February 14, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 10, 2022 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer |
|
| February 10, 2022 |
SRDX / SurModics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Surmodics Inc. Title of Class of Securities: Common Stock CUSIP Number: 868873100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule |
|
| February 10, 2022 |
SRDX / SurModics, Inc. / Trigran Investments, Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 Under the Securities Exchange Act of 1934 (Amendment No. 8)* SURMODICS, INC. (Name of Issuer) Common Stock, Par Value of $0.05 Per Share (Title of Class of Securities) 868873100 (CUSIP Number) December 31, 2021 Date of Event Which Requires Filing of the |
|
| February 10, 2022 |
CUSIP No. 868873100 Schedule 13G Page 1 of 1 Exhibit 1 EXHIBIT 1 TO SCHEDULE 13G February 10, 2022 In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, TRIGRAN INVESTMENTS, INC., DOUGLAS GRANAT, LAWRENCE A. OBERMAN, STEVEN G. SIMON, BRADLEY F. SIMON and STEVEN R. MONIESON each hereby agree to the joint filing of this statement on Schedule 13G (including any an |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name of registrant |
|
| February 4, 2022 |
SRDX / SurModics, Inc. / WELLINGTON TRUST Co N A - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* SurModics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 868873100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| February 4, 2022 |
SRDX / SurModics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* SurModics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 868873100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| February 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 3, 2022 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer |
|
| February 3, 2022 |
Surmodics Reports First Quarter Fiscal 2022 Results Exhibit 99.1 Surmodics Reports First Quarter Fiscal 2022 Results EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-February 3, 2022-Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 first quarter ended December 31, 2021. Summary of First Quarter and Recent Highlights Revenue of $23.0 m |
|
| January 11, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 11, 2022 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer |
|
| January 11, 2022 |
Exhibit 99.1 January 2022 Gary MaharajPresident and CEOTim ArensSenior Vice President of Finance, IT and CFO 1 ? 2022 Surmodics, Inc. CONFIDENTIAL All rights reserved. Some of the statements made during this presentation may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical or current facts, inclu |
|
| December 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| December 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| November 24, 2021 |
Subsidiaries of the Registrant. Exhibit 21 SURMODICS, INC. SUBSIDIARIES Name State of Incorporation Surmodics IVD, Inc. Maryland NorMedix, Inc. Minnesota Creagh Medical Limited Ireland SurModics MD, LLC Minnesota Surmodics MD Operations, LLC Minnesota Surmodics Coatings, LLC Minnesota Surmodics Coatings Mfg, LLC Minnesota Surmodics Holdings, LLC Minnesota Surmodics Shared Services, LLC Minnesota Vetex Medical Limited Ireland |
|
| November 24, 2021 |
Exhibit 10.27 Board Compensation Policy Surmodics, Inc. (Approved: September 23, 2021) Directors of Surmodics, Inc. (the ?Company?) that are not employed by the Company (?non-employee directors?) are entitled to the compensation set forth below for their service as a member of the Board of Directors (the ?Board?) of the Company. The Board reserves the right to amend this policy from time to time. |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-23837 Surmodics, Inc. |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 10, 2021 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer |
|
| November 10, 2021 |
Surmodics Reports Fourth Quarter Fiscal 2021 Results and Issues Fiscal 2022 Revenue and EPS Guidance Exhibit 99.1 Surmodics Reports Fourth Quarter Fiscal 2021 Results and Issues Fiscal 2022 Revenue and EPS Guidance EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-November 10, 2021-Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 fourth quarter ended September 30, 2021 and provided i |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 4, 2021 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Id |
|
| August 4, 2021 |
p UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q p UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name of registrant a |
|
| August 4, 2021 |
Surmodics Reports Third Quarter Fiscal 2021 Results and Updates Fiscal 2021 Revenue and EPS Guidance EX-99.1 2 a52471039ex991.htm EXHIBIT 99.1 Exhibit 99.1 Surmodics Reports Third Quarter Fiscal 2021 Results and Updates Fiscal 2021 Revenue and EPS Guidance EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-August 4, 2021-Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 third quarter e |
|
| July 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 2, 2021 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Iden |
|
| July 6, 2021 |
Surmodics Builds Thrombectomy Portfolio Exhibit 99.1 Surmodics Builds Thrombectomy Portfolio with Acquisition of Vetex Medical Limited Deal adds second FDA 510(k) cleared device to thrombectomy platform ? Easy-to-use, stand-alone, single session mechanical thrombectomy for removal of venous clot in highly attractive, rapidly growing and significantly under-penetrated market ? FDA 510(k) cleared (Dec. 2020) and CE Mark Certification (May |
|
| July 6, 2021 |
Exhibit 10.1 FIRST AMENDMENT TO Loan AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?) is made and entered into as of July 2, 2021, by and among Surmodics, Inc., a Minnesota corporation (?Borrower?), the other Loan Parties hereto, and Bridgewater Bank, a Minnesota banking corporation (together with its successors and assigns, ?Lender?). RECITALS: A.Borro |
|
| July 6, 2021 |
EX-2.2 3 srdx-ex22609.htm EX-2.2 Execution Version Exhibit 2.2 PUT AND CALL OPTION AGREEMENT SURMODICS MD, LLC THE PERSONS WHOSE NAMES AND ADDRESSES ARE SET OUT IN SCHEDULE 1 DATED 2 JULY 2021 Barrow Street Dublin 4, Ireland D04 TR29 DXII Dublin +353 1 614 5000 [email protected] MHC-25394119.4 This agreement is dated 2 July 2021. PARTIES (1) SURMODICS MD, LLC, a limited liability company organized und |
|
| July 6, 2021 |
Exhibit 2.1 Execution Version AGREEMENT FOR THE SALE AND PURCHASE OF SHARES IN THE CAPITAL OF VETEX MEDICAL LIMITED THE PERSONS WHOSE NAMES ARE SET OUT IN SCHEDULE 1 MARK BRUZZI SONASIAR LIMITED SURMODICS MD, LLC SURMODICS, INC. DATED 2 JULY 2021 MHC-25475944.3 TABLE OF CONTENTS 1 DEFINITIONS AND INTERPRETATION 4 2 SALE AND PURCHASE OF SHARES 15 3 COMPLETION 20 4 WARRANTIES 21 5 SPECIFIC INDEMNITI |
|
| July 6, 2021 |
? 2021 Surmodics, Inc. CONFIDENTIAL All rights reserved. 1 Surmodics Expands Thrombectomy Portfolio with Acquisition of Vetex Medical Limited Galway, Ireland Exhibit 99.2 Some of the statements made in this presentation may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical or current facts, includ |
|
| May 25, 2021 |
Exhibit 1.01 – Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form EXHIBIT 1.01 Conflict Minerals Report of Surmodics, Inc. This Conflict Minerals Report of Surmodics, Inc. (the ?Company?, ?we? or ?our?) for the period from January 1, 2020 to December 31, 2020, has been prepared pursuant to Rule 13p-1 and Form SD (together, the ?Rule?) promulgated under Section 13(p) of the Securities Exchange Act of 1934, as amended. The Rule requires disclosure of certain infor |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Surmodics, Inc. (Exact name of registrant as specified in its charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 9924 West 74th Street Eden Prairie, Minnesota 55344 (Address of Principal Executive Offices) (Zip Code) |
|
| April 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 28, 2021 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Id |
|
| April 28, 2021 |
Surmodics Reports Second Quarter Fiscal 2021 Results and Issues Fiscal 2021 Revenue and EPS Guidance Exhibit 99.1 Surmodics Reports Second Quarter Fiscal 2021 Results and Issues Fiscal 2021 Revenue and EPS Guidance EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-April 28, 2021-Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 second quarter ended March 31, 2021 and provided its fina |
|
| April 28, 2021 |
p UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name of registrant |
|
| February 16, 2021 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 11, 2021 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer |
|
| February 11, 2021 |
Exhibit 1 CUSIP No. 868873100 Schedule 13G EXHIBIT 1 TO SCHEDULE 13G February 11, 2021 In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, TRIGRAN INVESTMENTS, INC., DOUGLAS GRANAT, LAWRENCE A. OBERMAN, STEVEN G. SIMON, BRADLEY F. SIMON and STEVEN R. MONIESON each hereby agree to the joint filing of this statement on Schedule 13G (including any and all amendm |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 Under the Securities Exchange Act of 1934 (Amendment No. 1)* SURMODICS, INC. (Name of Issuer) Common Stock, Par Value of $0.05 Per Share (Title of Class of Securities) 868873100 (CUSIP Number) December 31, 2020 Date of Event Which Requires Filing of the |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 Under the Securities Exchange Act of 1934 (Amendment No. 7)* SURMODICS, INC. (Name of Issuer) Common Stock, Par Value of $0.05 Per Share (Title of Class of Securities) 868873100 (CUSIP Number) December 31, 2020 Date of Event Which Requires Filing of the |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Surmodics Inc. Title of Class of Securities: Common Stock CUSIP Number: 868873100 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| February 9, 2021 |
Surmodics Reports First Quarter Fiscal 2021 Results Exhibit 99.1 Surmodics Reports First Quarter Fiscal 2021 Results EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-February 9, 2021-Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 first quarter ended December 31, 2020. Summary of First Quarter and Recent Highlights Revenue of $22.3 m |
|
| February 9, 2021 |
p UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name of registra |
|
| February 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 9, 2021 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SurModics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 868873100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SurModics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 868873100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 28, 2021 |
Exhibit 99.1 Surmodics SurVeil™ Drug-Coated BalloonTRANSCEND Pivotal Trial 12-Month Results The Randomized And Controlled Noninferiority Trial to Evaluate Safety and Clinical Efficacy of the SurVeil™ Drug-Coated Balloon iN the Treatment of Subjects with Stenotic Lesions of the Femoropopliteal Artery Compared to the Medtronic IN.PACT® Admiral® Drug-Coated BalloonPresented at LINC 2021: Late Breakin |
|
| January 28, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 28, 2021 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer |
|
| December 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| December 22, 2020 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| December 18, 2020 |
As filed with the Securities and Exchange Commission on December 18, 2020 Registration No. |
|
| December 2, 2020 |
Exhibit 10.32 SURMODICS, INC. 2019 EQUITY INCENTIVE PLAN Restricted Stock Unit Award Agreement (Non-Employee Director) Surmodics, Inc. (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby grants an award of Restricted Stock Units to you, the Participant named below. The terms and conditions of this Award are set forth in this Restricted Stock Unit Award Agreement (the “ |
|
| December 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-23837 Surmodics, Inc. |
|
| December 2, 2020 |
Subsidiaries of the Registrant. Exhibit 21 SURMODICS, INC. SUBSIDIARIES Name State of Incorporation Surmodics IVD, Inc. Maryland NorMedix, Inc. Minnesota Creagh Medical Limited Ireland SurModics MD, LLC Minnesota Surmodics MD Operations, LLC Minnesota Surmodics Coatings, LLC Minnesota Surmodics Coatings Mfg, LLC Minnesota Surmodics Holdings, LLC Minnesota Surmodics Shared Services, LLC Minnesota |
|
| November 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 13, 2020 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer |
|
| November 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 4, 2020 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer |
|
| November 4, 2020 |
Surmodics Reports Fourth Quarter Fiscal 2020 Results Exhibit 99.1 Surmodics Reports Fourth Quarter Fiscal 2020 Results EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-November 4, 2020-Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 fourth quarter ended September 30, 2020. Summary of Fourth Quarter and Recent Highlights Revenue of $22 |
|
| September 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 18, 2020 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employe |
|
| September 15, 2020 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT dated as of September 14, 2020 among SURMODICS, INC. as Borrower, THE OTHER PARTIES HERETO THAT ARE DESIGNATED AS LOAN PARTIES and BRIDGEWATER BANK, as Lender TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 1.1 Defined Terms 1 1.2 UCC Definitions 13 1.3 Accounting Terms; GAAP 13 1.4 Terms Generally 13 ARTICLE 2 THE CREDIT FACILITIES 14 2.1 Revolving Facility |
|
| September 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 14, 2020 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employe |
|
| August 5, 2020 |
Surmodics Reports Third Quarter Fiscal 2020 Results Exhibit 99.1 Surmodics Reports Third Quarter Fiscal 2020 Results EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-August 5, 2020-Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 third quarter ended June 30, 2020. Summary of Third Quarter and Recent Highlights Revenue of $26.9 million |
|
| August 5, 2020 |
p UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name of registrant a |
|
| August 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 5, 2020 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Id |
|
| July 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 21, 2020 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Ide |
|
| July 21, 2020 |
POWER OF ATTORNEY I, Timothy J. Arens, hereby authorize and designate each of John Manders, Nicole J. Leimer, and Amra Hoso signing singly, as my true and lawful attorney-in-fact to: (1) execute for and on my behalf, in my capacity as an officer and/or director of Surmodics, Inc., a Minnesota corporation (the "Company"), the Forms 4 and 5 in accordance with Section 16(a) of the Securities Exchange |
|
| June 8, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 8, 2020 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Iden |
|
| June 8, 2020 |
Surmodics Receives CE Mark for its SurVeil™ Drug Coated Balloon Exhibit 99.1 Surmodics Receives CE Mark for its SurVeil™ Drug Coated Balloon Next generation device adds new technology to how physicians approach treatment of PAD EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-June 8, 2020-Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has received CE Mark Certification |
|
| May 27, 2020 |
United States securities and exchange commission logo May 26, 2020 Gordon S. Weber Senior Vice President, General Counsel and Secretary Surmodics, Inc. 9924 West 74th Street Eden Prairie, Minnesota 55344 Re: Surmodics, Inc. Registration Statement on Form S-3 Filed May 22, 2020 File No. 333-238611 Dear Mr. Weber: This is to advise you that we have not reviewed and will not review your registration |
|
| May 27, 2020 |
United States securities and exchange commission logo May 26, 2020 Gordon S. Weber Senior Vice President, General Counsel and Secretary Surmodics, Inc. 9924 West 74th Street Eden Prairie, Minnesota 55344 Re: Surmodics, Inc. Registration Statement on Form S-3 Filed May 22, 2020 File No. 333-238611 Dear Mr. Weber: This is to advise you that we have not reviewed and will not review your registration |
|
| May 27, 2020 |
Surmodics, Inc. 9924 West 74th Street Eden Prairie, Minnesota 55344 May 27, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Surmodics, Inc. Registration Statement on Form S-3 File No. 333-238611 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Surmodics, Inc. hereby respectfully |
|
| May 22, 2020 |
Exhibit 24.1 SURMODICS, INC. Power of Attorney KNOW ALL MEN BY THESE PRESENTS, that the undersigned director and/or officer of Surmodics, Inc., a Minnesota corporation, does hereby make, constitute and appoint Gary R. Maharaj, Timothy J. Arens, John D. Manders and Gordon S. Weber, and each of them, acting singly, the undersigned’s true and lawful attorney-in-fact, with power of substitution, for t |
|
| May 22, 2020 |
As filed with the Securities and Exchange Commission on May 22, 2020 Registration No. |
|
| April 30, 2020 |
Quarterly Report - Q2 FY20 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name of registrant as |
|
| April 29, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 29, 2020 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Id |
|
| April 29, 2020 |
Surmodics Reports Second Quarter Fiscal 2020 Results and Provides COVID-19 Pandemic Update Exhibit 99.1 Surmodics Reports Second Quarter Fiscal 2020 Results and Provides COVID-19 Pandemic Update EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-April 29, 2020-Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 second quarter ended March 31, 2020, and suspended its financial gu |
|
| March 25, 2020 |
SRDX / SurModics, Inc. / Trigran Investments, Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 Under the Securities Exchange Act of 1934 (Amendment No. 6)* Surmodics, Inc. (Name of Issuer) Common Stock, $0.05 par value (Title of Class of Securities) 868873100 (CUSIP Number) March 16, 2020 Date of Event Which Requires Filing of the Statement Check |
|
| March 25, 2020 |
Exhibit 1 EXHIBIT 1 TO SCHEDULE 13G March 24, 2020 In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, TRIGRAN INVESTMENTS, INC. |
|
| March 25, 2020 |
SRDX / SurModics, Inc. / TRIGRAN INVESTMENTS LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 Under the Securities Exchange Act of 1934 (Amendment No. )* Surmodics, Inc. (Name of Issuer) Common Stock, $0.05 par value (Title of Class of Securities) 868873100 (CUSIP Number) March 16, 2020 Date of Event Which Requires Filing of the Statement Check t |
|
| February 18, 2020 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 13, 2020 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer |
|
| February 12, 2020 |
SRDX / SurModics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Surmodics Inc Title of Class of Securities: Common Stock CUSIP Number: 868873100 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| February 12, 2020 |
SRDX / SurModics, Inc. / Trigran Investments, Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 Under the Securities Exchange Act of 1934 (Amendment No. 5)* Surmodics, Inc. (Name of Issuer) Common Stock, $0.05 par value (Title of Class of Securities) 868873100 (CUSIP Number) December 31, 2019 Date of Event Which Requires Filing of the Statement Che |
|
| February 12, 2020 |
Exhibit 1 EXHIBIT 1 TO SCHEDULE 13G February 12, 2020 In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, TRIGRAN INVESTMENTS, INC. |
|
| February 7, 2020 |
EXHIBIT 10.1 FORM OF CHANGE OF CONTROL AGREEMENT Parties: Surmodics, Inc. (“Company”) 9924 West 74th Street Eden Prairie, MN 55344-3523 (“Executive”) Date: RECITALS: 1. Executive currently serves as the of the Company, and Executive has extensive knowledge and experience relating to the Company’s business. 2. The parties recognize that a “Change of Control” may materially change or diminish Execut |
|
| February 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name of registrant |
|
| February 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 5, 2020 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer |
|
| February 5, 2020 |
Surmodics Reports First Quarter Fiscal 2020 Results Exhibit 99.1 Surmodics Reports First Quarter Fiscal 2020 Results EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-February 5, 2020-Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 first quarter ended December 31, 2019. Summary of First Quarter and Recent Highlights Revenue of $22.6 m |
|
| December 23, 2019 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| December 23, 2019 |
SRDX / SurModics, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| December 10, 2019 |
SRDX / SurModics, Inc. / Trigran Investments, Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 Under the Securities Exchange Act of 1934 (Amendment No. 4)* Surmodics, Inc. (Name of Issuer) Common Stock, $0.05 par value (Title of Class of Securities) 868873100 (CUSIP Number) November 7, 2019 Date of Event Which Requires Filing of the Statement Chec |
|
| December 10, 2019 |
Exhibit 1 EXHIBIT 1 TO SCHEDULE 13G December 10, 2019 In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, TRIGRAN INVESTMENTS, INC. |
|
| December 3, 2019 |
j UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-23837 SURMODICS, INC. |
|
| December 3, 2019 |
Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES Name State of Incorporation Surmodics IVD, Inc. Maryland NorMedix, Inc. Minnesota Creagh Medical Limited Ireland USCI Ireland Limited Ireland SurModics MD, LLC Minnesota Surmodics MD Operations, LLC Minnesota Surmodics Coatings, LLC Minnesota Surmodics Coatings Mfg, LLC Minnesota Surmodics Holdings, LLC Minnesota Surmodics Shared Services, LLC Minnesota |
|
| December 3, 2019 |
Exhibit 4.1 DESCRIPTION OF SECURITIES The summary of the general terms and provisions of the capital stock of Surmodics, Inc. (the “Company”) set forth below does not purport to be complete and is subject to and qualified by reference to the Company’s Restated Articles of Incorporation, as amended (the “Articles”) and Restated Bylaws, as amended (the “Bylaws” and together with the Articles, the “C |
|
| November 14, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 8, 2019 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Emplo |
|
| October 31, 2019 |
Surmodics Reports Fourth Quarter Fiscal 2019 Results and Issues Fiscal 2020 Revenue and EPS Guidance Exhibit 99.1 Surmodics Reports Fourth Quarter Fiscal 2019 Results and Issues Fiscal 2020 Revenue and EPS Guidance EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-October 31, 2019-Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 fourth quarter ended September 30, 2019, and provided i |
|
| October 31, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 31, 2019 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer |
|
| August 28, 2019 |
Surmodics Completes Enrollment in Pivotal TRANSCEND Clinical Trial Exhibit 99.1 Surmodics Completes Enrollment in Pivotal TRANSCEND Clinical Trial Study designed to evaluate safety, efficacy of the company’s next-generation SurVeil™ drug-coated balloon Company Raises 2019 Revenue and EPS Guidance EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-August 28, 2019-Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healt |
|
| August 28, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 28, 2019 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer I |
|
| August 12, 2019 |
Exhibit 99.1 Gary MaharajPresident and CEOTim ArensVice President of Finance and CFOAugust 2019 1 Safe Harbor Some of the statements made during this presentation may be considered forward-looking statements. Statements that are not historical or current facts, including statements about beliefs and expectations regarding our performance in the near- and long-term, including our revenue and earnin |
|
| August 12, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 12, 2019 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer I |
|
| August 1, 2019 |
Surmodics, Inc. Board Compensation Policy, Amended and restated as of May 14, 2019. EXHIBIT 10.1 Board Compensation Policy Surmodics, Inc. (Approved: May 14, 2019) Directors of Surmodics, Inc. (the “Company”) that are not employed by the Company (“non-employee directors”) are entitled to the compensation set forth below for their service as a member of the Board of Directors (the “Board”) of the Company. The Board reserves the right to amend this policy from time to time. Unless |
|
| August 1, 2019 |
SRDX / SurModics, Inc. 10-Q - Quarterly Report - SRDX-Q3 2019 - 6.30.2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name of registrant as |
|
| July 31, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 31, 2019 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Ide |
|
| July 31, 2019 |
Surmodics Reports Third Quarter Fiscal 2019 Results and Raises Fiscal 2019 Revenue and EPS Guidance Exhibit 99.1 Surmodics Reports Third Quarter Fiscal 2019 Results and Raises Fiscal 2019 Revenue and EPS Guidance EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-July 31, 2019-Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 third quarter ended June 30, 2019, and updated its financia |
|
| May 6, 2019 |
EX-10.5 Exhibit 10.5 SURMODICS, INC. 2019 EQUITY INCENTIVE PLAN Restricted Stock Unit Award Agreement (Director) SurModics, Inc. (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby grants an award of Restricted Stock Units to you, the Participant named below. The terms and conditions of this Award are set forth in this Restricted Stock Unit Award Agreement (the “Agreem |
|
| May 6, 2019 |
EX-10.2 Exhibit 10.2 SURMODICS, INC. 2019 EQUITY INCENTIVE PLAN Restricted Stock Award Agreement SurModics, Inc. (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby grants to you, the Participant named below, an award of shares of the Company’s common stock whose vesting is subject to satisfaction of service-based conditions (the “Restricted Shares”). The terms and con |
|
| May 6, 2019 |
EX-10.3 Exhibit 10.3 SURMODICS, INC. 2019 EQUITY INCENTIVE PLAN Restricted Stock Unit Award Agreement (Employee) SurModics, Inc. (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby grants an award of Restricted Stock Units to you, the Participant named below. The terms and conditions of this Award are set forth in this Restricted Stock Unit Award Agreement (the “Agreem |
|
| May 6, 2019 |
Form of Performance Stock Unit Award Agreement. EX-10.4 Exhibit 10.4 SURMODICS, INC. 2019 EQUITY INCENTIVE PLAN Performance Stock Unit Award Agreement SurModics, Inc. (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby grants an award of Performance Stock Units to you, the Participant named below. The terms and conditions of this Award are set forth in this Performance Stock Unit Agreement (the “Agreement”), consist |
|
| May 6, 2019 |
EX-10.1 Exhibit 10.1 SURMODICS, INC. 2019 EQUITY INCENTIVE PLAN Non-Qualified Stock Option Award Agreement SurModics, Inc. (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby grants an Option to purchase shares of the Company’s common stock to you, the Participant named below. The terms and conditions of the Option Award are set forth in this Non-Qualified Stock Option |
|
| May 6, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2019 Surmodics, Inc. |
|
| May 6, 2019 |
EX-10.6 Exhibit 10.6 SURMODICS, INC. 2019 EQUITY INCENTIVE PLAN Deferred Stock Unit Master Agreement (Quarterly Awards) This is a Deferred Stock Unit Master Agreement (the “Agreement”), effective as of , 20 , between SurModics, Inc., a Minnesota corporation (the “Company”), and you, . Any capitalized term used but not defined in this Agreement shall have the meaning set forth in the Company’s 2019 |
|
| May 3, 2019 |
SRDX / SurModics, Inc. S-8 S-8 S-8 As filed with the Securities and Exchange Commission on May 3, 2019 Registration No. |
|
| May 3, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-23837 Surmodics, Inc. (Exact name of registrant as |
|
| May 1, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 1, 2019 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Ident |
|
| May 1, 2019 |
Surmodics Reports Second Quarter Fiscal 2019 Results Updates Fiscal 2019 Guidance Exhibit 99.1 Surmodics Reports Second Quarter Fiscal 2019 Results Updates Fiscal 2019 Guidance EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-May 1, 2019-Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 second quarter ended March 31, 2019, and updated its financial outlook for fisc |
|
| April 17, 2019 |
Surmodics Provides Update Regarding TRANSCEND Clinical Trial Exhibit 99.1 Surmodics Provides Update Regarding TRANSCEND Clinical Trial EDEN PRAIRIE, Minn.-(BUSINESS WIRE)-April 17, 2019-Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, has resumed patient enrollment into its TRANSCEND clinical trial and is nearly 75 percent of the way to its goal of 446 randomized patients. |
|
| April 17, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 17, 2019 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Id |
|
| April 9, 2019 |
Gary MaharajPresident and CEOTim ArensVice President of Finance and CFOAPRIL 2019 1 Exhibit 99.1 Gary MaharajPresident and CEOTim ArensVice President of Finance and CFOAPRIL 2019 1 Safe Harbor Some of the statements made during this presentation may be considered forward-looking statements. Statements that are not historical or current facts, including statements about beliefs and expectations regarding our performance in the near- and long-term, including our revenue and earning |
|
| April 9, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 9, 2019 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employer Ide |
|
| March 18, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 15, 2019 Date of report (Date of earliest event reported) Surmodics, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-23837 41-1356149 (State of Incorporation) (Commission File Number) (I.R.S. Employe |
